GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Loans Receivable

Abivax (Abivax) Loans Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Abivax Loans Receivable?

Abivax's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


Abivax Loans Receivable Historical Data

The historical data trend for Abivax's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Loans Receivable Chart

Abivax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abivax Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Abivax Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Abivax Loans Receivable Related Terms

Thank you for viewing the detailed overview of Abivax's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Abivax (Abivax) Business Description

Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.